Tardive dyskinesia (TD) is a potentially chronic condition that can arise following use of dopamine receptor blocking agents, including antipsychotics and metoclopramide. The signs of TD include involuntary movements of the face, mouth, trunk, and extremities. These movements (or TD) may impact patients’ lives and those who care for them. There are currently no medications approved by the FDA indicated for the treatment of TD.
It is estimated that at least 500,000 people in the US are affected by Tardive Dyskinesia.